TVTX
Travere TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
TVTX Profile
Travere Therapeutics, Inc.
A company that developing therapies to treat rare disorders like nephrology, hepatology, and metabolism
3611 Valley Centre Drive, Suite 300, San Diego, CA 92130
--
Travere Therapeutics, Inc., incorporated as Desert Gatewayinc on February 8, 2008, is registered in Oklahoma.
Retrophin is a developing biopharmaceutical company dedicated to the development, acquisition and commercialization of therapeutic therapies for serious, catastrophic and rare diseases. In the United States, Retrophin is working on the development of SyntocinonTM Nasal Spray to aid postpartum milk secretion and can be used to treat schizophrenia and autism. Syntocinon Nasal Spray is currently marketed by Novartis and Sigma-Tau in Europe and other countries to help pregnant women with postpartum milk secretion. In addition, Retrophin is developing RE-034, a synthetic hormone analog consisting of 24 of the 39 amino acids contained in ACTH, for the treatment of infantile spasms and nephrotic syndrome. Retrophin is also working on re-024, a new small molecule for the potential treatment of pantothenate neurodegenerative disease. At the same time, the company is developing sparsentan, formerly known as re-021, a dual-acting angiotensin receptor and endothelin receptor for the treatment of focal segmental glomerulosclerosis. Retrophin also has several additional programs in clinical development, including re-001, for the treatment of Duchenne muscular dystrophy.
